CN Patent

CN113248521B — 一种k-ras g12c抑制剂及其制备方法和应用

Assigned to Abbisko Therapeutics Co Ltd · Expires 2023-07-18 · 3y expired

What this patent protects

本发明涉及一种具有式(Ⅰ)结构的K‑RAS G12C抑制剂及其制备方法和应用。本发明系列化合物可广泛应用于制备治疗至少部分由K‑RAS G12C突变介导的肿瘤或癌症的药物，特别是治疗肺部、肝胆、胃肠道、血液系统、皮肤、骨、泌尿生殖道、神经系统、妇科性和肾上腺相关恶性肿瘤或癌症的药物，有望开发成新一代K‑RAS G12C抑制剂药物。

USPTO Abstract

本发明涉及一种具有式(Ⅰ)结构的K‑RAS G12C抑制剂及其制备方法和应用。本发明系列化合物可广泛应用于制备治疗至少部分由K‑RAS G12C突变介导的肿瘤或癌症的药物，特别是治疗肺部、肝胆、胃肠道、血液系统、皮肤、骨、泌尿生殖道、神经系统、妇科性和肾上腺相关恶性肿瘤或癌症的药物，有望开发成新一代K‑RAS G12C抑制剂药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN113248521B
Jurisdiction
CN
Classification
—
Expires
2023-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Abbisko Therapeutics Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.